How can the effectiveness of existing curative therapies be improved for allogeneic hematopoietic stem cell transplantation?
How can the use of CAR T-cell and checkpoint blockade strategies be optimized in order to cure hematologic diseases?
CAR therapy has resurrected the role of immunotherapy in treating cancer. But it has significant toxicity. Can we train , standardize the care of and adequately oversee the care of patients getting CAR therapy , especially as company begin to approach FDA for approval of this therapy and up scale for mass treatment.
As the current chair of the Research and Training Division, I would like to convey that the AAAAI membership would like the NHLBI to consider the following in the development of its strategic plan: What role should sublingual immunotherapy play in the treatment of asthma?